Hengyang Mosynex Biotechnology Co., Ltd. – Trademark Portfolio

Entity Type: 99

Hengyang Mosynex Biotechnology Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include MOSYNEX. The owner is based in Hengyang.

Room 1218, Basement 1-4, Tianchou Zijin Garden,

No. 41 Outer Ring Road, Hi-Tech Zone

Hengyang 421200 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

MOSYNEX
MOSYNEX
Registered 2025

Trademark Classifications

Hengyang Mosynex Biotechnology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does Hengyang Mosynex Biotechnology Co., Ltd. have?

Hengyang Mosynex Biotechnology Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Hengyang Mosynex Biotechnology Co., Ltd. file in?

Hengyang Mosynex Biotechnology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 1 (Chemicals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are Hengyang Mosynex Biotechnology Co., Ltd.'s most well-known trademarks?

Hengyang Mosynex Biotechnology Co., Ltd.'s registered trademark portfolio includes well-known marks such as MOSYNEX. These are among 1 currently registered trademark in the portfolio.

What is Hengyang Mosynex Biotechnology Co., Ltd.'s trademark registration success rate?

Hengyang Mosynex Biotechnology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.